Roche’s ulcerative colitis drug etrolizumab looks shaky afte...

Roche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans firmly towards the latter.

J&J gets Stelara okay in Europe for ulcerative colitis

Allergan says it will shed two drugs as AbbVie takeover loom...

FDA approves oral treatment for ulcerative colitis

Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.

Gilead to collaborate with Google’s Verily in inflammatory d...

Gilead has signed a three-year deal with Google’s life science division Verily to work on identifying the immunological and molecular drivers behind three inflammatory diseases.

Janssen inks potential $1bn deal for IBD drug

Janssen has swooped to buy rights to an early-stage oral inflammatory bowel disease drug from Protagonist Therapeutics in a deal worth up to $1 billion.